Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Host-Directed Therapeutic Strategies for Tuberculosis.

Kolloli A, Subbian S.

Front Med (Lausanne). 2017 Oct 18;4:171. doi: 10.3389/fmed.2017.00171. eCollection 2017. Review.

2.

Paradoxical response with increased tumor necrosis factor-α levels to anti-tuberculosis treatment in a patient with disseminated tuberculosis.

Watanabe S, Kaneko Y, Kawamoto H, Maehara T, Baba Y, Fujisaki I, Saito N, Ryu K, Seki A, Horikiri T, Kinoshita A, Takeda H, Saito K, Kuwano K.

Respir Med Case Rep. 2017 Feb 28;20:201-204. doi: 10.1016/j.rmcr.2017.02.011. eCollection 2017.

3.

Corticosteroids for tuberculous pleurisy.

Ryan H, Yoo J, Darsini P.

Cochrane Database Syst Rev. 2017 Mar 14;3:CD001876. doi: 10.1002/14651858.CD001876.pub3. Review.

4.

Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial).

Stek C, Schutz C, Blumenthal L, Thienemann F, Buyze J, Nöstlinger C, Ravinetto R, Wouters E, Colebunders R, Maartens G, Wilkinson RJ, Lynen L, Meintjes G.

JMIR Res Protoc. 2016 Aug 29;5(3):e173. doi: 10.2196/resprot.6046.

5.

Immunotherapy for tuberculosis: future prospects.

Abate G, Hoft DF.

Immunotargets Ther. 2016 Apr 20;5:37-45. doi: 10.2147/ITT.S81892. eCollection 2016. Review.

6.

Extremely high HIV-1 viral load in a patient with undiagnosed clinical indicator disease for HIV infection.

Flanagan S, De Saram S, Dhairyawan R.

BMJ Case Rep. 2015 Nov 24;2015. pii: bcr2015210213. doi: 10.1136/bcr-2015-210213.

7.

Targeting Batf2 for infectious diseases and cancer.

Guler R, Roy S, Suzuki H, Brombacher F.

Oncotarget. 2015 Sep 29;6(29):26575-82. doi: 10.18632/oncotarget.5576.

8.

Immunoadjuvant Therapy and Noninvasive Ventilation for Acute Respiratory Failure in Lung Tuberculosis: A Case Study.

Flores-Franco RA, Olivas-Medina DA, Pacheco-Tena CF, Duque-Rodríguez J.

Case Rep Pulmonol. 2015;2015:283867. doi: 10.1155/2015/283867. Epub 2015 Jul 27.

9.

Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge.

Bisson GP, Zetola N, Collman RG.

Curr HIV/AIDS Rep. 2015 Mar;12(1):107-16. doi: 10.1007/s11904-015-0256-x. Review.

10.

Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis.

Wallis RS.

Open Forum Infect Dis. 2014 Jun 3;1(1):ofu020. doi: 10.1093/ofid/ofu020. eCollection 2014 Mar.

11.

Tuberculosis vaccines and prevention of infection.

Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker LG, Self SG.

Microbiol Mol Biol Rev. 2014 Dec;78(4):650-71. doi: 10.1128/MMBR.00021-14. Review.

12.
13.

Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy.

Shim TS.

Tuberc Respir Dis (Seoul). 2014 Jun;76(6):261-8. doi: 10.4046/trd.2014.76.6.261. Epub 2014 Jun 28. Review.

14.

Wasting among Uganda men with pulmonary tuberculosis is associated with linear regain in lean tissue mass during and after treatment in contrast to women with wasting who regain fat tissue mass: prospective cohort study.

Mupere E, Malone L, Zalwango S, Okwera A, Nsereko M, Tisch DJ, Parraga IM, Stein CM, Mugerwa R, Boom WH, Mayanja HK, Whalen CC; Tuberculosis Research Unit at Case Western Reserve University.

BMC Infect Dis. 2014 Jan 13;14:24. doi: 10.1186/1471-2334-14-24.

15.

Novel adjunctive therapies for the treatment of tuberculosis.

Ordonez AA, Maiga M, Gupta S, Weinstein EA, Bishai WR, Jain SK.

Curr Mol Med. 2014 Mar;14(3):385-95. Review.

16.

Complement factor C7 contributes to lung immunopathology caused by Mycobacterium tuberculosis.

Welsh KJ, Lewis CT, Boyd S, Braun MC, Actor JK.

Clin Dev Immunol. 2012;2012:429675. doi: 10.1155/2012/429675. Epub 2012 Jul 30.

17.

Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome.

Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, Tadokera R, Conesa-Botella A, Seldon R, Rangaka MX, Rebe K, Pepper DJ, Morroni C, Colebunders R, Maartens G, Wilkinson RJ.

Am J Respir Crit Care Med. 2012 Aug 15;186(4):369-77. doi: 10.1164/rccm.201201-0094OC. Epub 2012 Jun 14.

18.

Lean tissue mass wasting is associated with increased risk of mortality among women with pulmonary tuberculosis in urban Uganda.

Mupere E, Malone L, Zalwango S, Chiunda A, Okwera A, Parraga I, Stein CM, Tisch DJ, Mugerwa R, Boom WH, Mayanja H, Whalen CC.

Ann Epidemiol. 2012 Jul;22(7):466-73. doi: 10.1016/j.annepidem.2012.04.007. Epub 2012 May 9.

19.

Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.

Maiga M, Agarwal N, Ammerman NC, Gupta R, Guo H, Maiga MC, Lun S, Bishai WR.

PLoS One. 2012;7(2):e30749. doi: 10.1371/journal.pone.0030749. Epub 2012 Feb 3.

20.

Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections.

Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray JP, Ko DC, Zou Y, Bang ND, Chau TT, Vary JC, Hawn TR, Dunstan SJ, Farrar JJ, Thwaites GE, King MC, Serhan CN, Ramakrishnan L.

Cell. 2012 Feb 3;148(3):434-46. doi: 10.1016/j.cell.2011.12.023.

Supplemental Content

Support Center